Author:
Landen Charles N.,Lu Chunhua,Han Liz Y.,Coffman Karen T.,Bruckheimer Elizabeth,Halder Jyotsnabaran,Mangala Lingegowda S.,Merritt William M.,Lin Yvonne G.,Gao Changhou,Schmandt Rosemarie,Kamat Aparna A.,Li Yang,Thaker Premal,Gershenson David M.,Parikh Nila U.,Gallick Gary E.,Kinch Michael S.,Sood Anil K.
Publisher
Oxford University Press (OUP)
Reference65 articles.
1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin2006 ; 56 : 106 –30.
2. Lister-Sharp D, McDonagh MS, Khan KS, Kleijnen J. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer. Health Technol Assess2000 ; 4 (17): 1 –113.
3. Hoskins W, Perez C, Young R, Barakat R, Markman M, Randall M. Principles and practice of gynecologic oncology. 4th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2005 .
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med2004 ; 350 : 2335 –42.
5. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov2004 ; 3 : 391 –400.
Cited by
115 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献